Free tool
FAERS Monitor: Glycophos
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220381 or its brand name (Glycophos, Sodium Glycerophosphate). Reports on generic versions are filed under their own applications.
Reports
364
Serious
358
98% of reports
Hospitalization
213
Death reported
52
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malaise47
- pyrexia43
- vomiting30
- nausea29
- chills26
- dyspnoea26
- body temperature increased19
- death18
- device related infection17
- tremor17
- diarrhoea16
- abdominal pain15
- product preparation error14
- chest pain12
- fatigue12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2014 | 19 |
| 2015 | 7 |
| 2016 | 22 |
| 2017 | 23 |
| 2018 | 72 |
| 2019 | 40 |
| 2020 | 13 |
| 2021 | 19 |
| 2022 | 22 |
| 2023 | 32 |
| 2024 | 25 |
| 2025 | 13 |
| 2026 | 55 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,795 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device related infectionSignal | 17 | 63.9 | 40.2 | 990 |
| body temperature increasedSignal | 19 | 53.9 | 34.8 | 934 |
| product preparation errorSignal | 14 | 39.4 | 23.6 | 486 |
| chillsSignal | 26 | 12.8 | 8.8 | 273 |
| pyrexiaSignal | 43 | 7.2 | 5.4 | 226 |
| malaiseSignal | 47 | 6.2 | 4.7 | 204 |
| tremorSignal | 17 | 5.9 | 3.7 | 65 |
| chest painSignal | 12 | 3.7 | 2.1 | 22 |
| abdominal painSignal | 15 | 3.7 | 2.3 | 28 |
| vomitingSignal | 30 | 3.7 | 2.6 | 57 |
| dyspnoeaSignal | 26 | 2.7 | 1.8 | 26 |
| nauseaSignal | 29 | 2.1 | 1.5 | 17 |
| diarrhoea | 16 | 1.4 | 0.9 | 2 |
| death | 18 | 1.2 | 0.8 | 0 |
| fatigue | 12 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.